Clinical trials: Respiratory Viruses
Respiratory Syncytial Virus
Pre-Approval Access to JNJ-53718678 for the Treatment of Respiratory Syncytial Virus (RSV) Infection in (a) Immunocompromised Adult and Pediatric Participants
The purpose of this pre-approval access program is to provide treatment to immunocompromised participants with serious/life-threatening diseases or conditions (Respiratory Syncytial Virus [RSV] infection) and to collect the…
- Trial name
- NCT04221412
- Testing
- JNJ-53718678
- Sponsor
- Janssen Sciences Ireland UC
Knowledge, Attitudes, Practice, Covid19
mHealth Intervention for Increasing COVID-19 Prevention Practices With Urban Refugee and Displaced Youth in Uganda
Uganda hosts 1.4 million refugees, making it Sub-Saharan Africa's largest refugee host community and the third largest globally.
- Trial name
- NCT04631367
- Testing
- Kukaa Salama: mHealth intervention, Face Mask + Soap
- Where
- Canada
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Coronavirus Disease 2019
Evolution of Coronavirus Disease 2019 (COVID-19) Patients in Extremadura
At the end of January 2020, the international community was informed of the presence of a new viral disease that started in Wuhan (China) and spread rapidly throughout the world.
- Trial name
- COVIXTREM (NCT04724850)
- Where
- Spain
- Volunteers
- 440 people
- Sponsor
- Juan Fernando Masa Jiménez
Cognitive Dysfunction, Acquired Brain Injury
Fareon Open Label Device Clinical Trial
The purpose of this study is to assess the safety and feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to acquired brain injury, Long COVID, traumatic brain injury, myalgic encephalomyelitis…
- Conditions
- Cognitive Dysfunction, Acquired Brain Injury, Traumatic Brain Injury
- Trial name
- NCT07600320
- Testing
- Fareon device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Influenza Immunization
Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.
The purpose of this study was to demonstrate the non-inferiority (NI) of the HAI immune response of RIV4 in participants aged 9 to 17 years vs participants aged 18 to 49 years and to describe the immunogenicity and safety profile…
- Trial name
- NCT05513053
- Testing
- Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH
- Where
- 35 sites in United States, Czechia and 2 more
- Volunteers
- 1,308 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
COVID-19, Asymptomatic Pregnant
COVID-19 PCR Test Results in Asymptomatic Pregnants
In order to prevent contamination from the pregnant women hospitalized in this clinic, the RT-PCR test is performed from the oropharyngeal and nasal swab sample taken before hospitalization.
- Trial name
- NCT04410939
- Testing
- Reverse transcription polymerase chain reaction
- Where
- Turkey (Türkiye)
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Istanbul Medipol University Hospital
Viral Respiratory Tract Infection
Acupuncture for Acute Viral Lower Respiratory Infection in Hospitalized Children
Acute viral respiratory infections are among the most common causes of hospitalization in the pediatric population. The usual presentation of viral respiratory tract infections (VRTI) includes fever, malaise, wheezing and or…
- Trial name
- NCT02640066
- Testing
- acupuncture
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Ziv Hospital
Influenza
Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics
The purpose of this study was to evaluate dose-related safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine, administered to healthy children aged 6 to…
- Trial name
- NCT00336453
- Testing
- Influenza Vaccination
- Where
- 3 sites in United States
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
COVID-19
Attitude and Perception Towards COVID-19 Pandemic
Assess response and attitude of general population living in Sharkia Governerate, Egypt as regard COVID-19 pandemic through arabic questionnaire.
- Trial name
- NCT04400812
- Testing
- questionnaire
- Where
- Egypt
- Volunteers
- 5,000 people
- Sponsor
- Zagazig University
Diphtheria, Tetanus
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
This is a follow-up of the primary series vaccination schedule in Study A3L24 (NCT01177722). The objectives are: To describe the antibody persistence to any antigen contained in the investigational DTaP-IPV-Hep B-PRP-T vaccine…
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01444781
- Testing
- DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide, DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide, DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine
- Where
- 2 sites in Colombia, Costa Rica
- Volunteers
- 1,106 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
ARDS Due to COVID-19
Ventilator Strategies in ICU Patients With COVID-19 - a National-wide Retrospective Observational Study.
Mechanical ventilation is likely lifesaving in patients with coronavirus disease 2019 (COVID-19) but may also result in adverse events.
- Trial name
- NCT05102630
- Where
- 2 sites in Denmark
- Volunteers
- 1,193 people
- Sponsor
- University of Southern Denmark
Viral Bronchiolitis
Hypertonic Saline to Reduce Hospital Admissions in Bronchiolitis
Inhaled 3% hypertonic saline (HS) administered every 2-8 hours to infants admitted to hospital with viral bronchiolitis has been shown to improve airway clearance and reduces length of stay.
- Trial name
- NCT00677729
- Testing
- solution contains 1 mg salbutamol plus 3% hypertonic saline, solution contains 1 mg salbutamol plus 0.9% saline
- Where
- 3 sites in Canada
- Volunteers
- 81 people
- Sponsor
- Queen's University
COVID-19, Corona Virus Infection
Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence
The 2019-2020 COVID-19 pandemic is the largest outbreak in recent history. It is not known how long after someone gets sick with COVID-19 and recovers that they can still infect other people.
- Conditions
- COVID-19, Corona Virus Infection, SARS-CoV 2
- Trial name
- C-PIC (NCT04448145)
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Columbia University
Coronavirus Disease (COVID-19), COVID-19
Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19
Retrospective study from November 2019 -Febrauary 2020 on severe respiratory illness to access the presence or absence of COVID-19 in patients samples by real-time PcR
- Trial name
- Explore (NCT04346056)
- Where
- 2 sites in Egypt
- Volunteers
- 500 people
- Sponsor
- Ain Shams University
Vaccination; Infection, Covid19
Risk of COVID-19 Infection After Vaccination
The purpose of this observational nationwide study is to evaluate the effects of three different COVID-19 vaccines for the outcome of different severities of incident COVID infection.
- Trial name
- NCT04848441
- Testing
- The COVID-19 vaccines BNT162b2, mRNA-1273 and ChAdOx1
- Volunteers
- 2,000,000 people
- Sponsor
- Umeå University
Acute Kidney Injury, Covid19
Renal Involvement in Hospitalized Children With COVID-19
Covid-19 is an important human and animal pathogen, it mostly causes respiratory and gastrointestinal symptoms. Clinical features range from a common cold to severe diseases such as severe acute respiratory distress syndrome…
- Conditions
- Acute Kidney Injury, Covid19, Renal Dysfunction, Coronavirus Infection
- Trial name
- RIHCC (NCT04788394)
- Testing
- data review, data comparing
- Where
- Qatar
- Volunteers
- 400 people
- Sponsor
- Hamad Medical Corporation
COVID-19, Myocardial Reperfusion Injury
Myocardial Injury and Major Adverse Outcomes in Patients With COVID-19
The study will analyze the incidence, clinical outcomes and predictors of myocardial injury in a large patient population with COVID-19 treated in Mount Sinai Hospital (MSH) system.
- Conditions
- COVID-19, Myocardial Reperfusion Injury, Cardiovascular Diseases
- Trial name
- NCT04397939
- Where
- United States
- Volunteers
- 4,695 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Respiratory Syncytial Virus
A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants
The purpose of the study is to learn about the safety and immune activity of the RSVpreF vaccine. It will be studied in infants born to mothers living with HIV.
- Trial name
- MORISOT (NCT06325657)
- Testing
- RSVpreF vaccine, Placebp
- Where
- 14 sites in South Africa
- Volunteers
- 681 people
- Sponsor
- Pfizer
Covid19, Children, Only
SeroCovid<19: Covid-19 Seroconversion in Tertiary Pediatric Patients
Children are relatively spared from the direct clinical impact of COVID-19. Pediatric patients with regular follow-up at tertiary pediatric centres and presenting one or more chronic conditions might be at increased risk for…
- Trial name
- NCT04615000
- Testing
- SARS-CoV-2 serological assessment (IgG)
- Where
- Belgium
- Volunteers
- 362 people
- Sponsor
- University Hospital, Ghent
Acute Rhinosinusitis
Non-interventional Study of Ectoin Nasal Douche (END01) in Patients With Acute Viral Rhinosinusitis
The goal of this non interventional study is to investigate the efficacy, tolerability and safety of the newly developed Ectoin Nasal Douche END01.
- Trial name
- NCT03480100
- Testing
- Xylometazoline Nasal Spray, Ectoin Nasal Douche
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Bitop AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.